# ImmuCell Corporation (ICCC)

Source: https://www.quantisnow.com/company/ICCC
Generated: 2026-11-10T22:11:12.261Z

- Ticker: ICCC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IPO year: 1987
- SEC CIK: 0000811641
- Website: immucell.com

## About

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

## Latest ICCC news and filings

- 2026-11-06 21:05 UTC [Earnings Date] [ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026](https://www.quantisnow.com/insight/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-6778818)
- 2026-10-13 10:01 UTC [SEC Form 8-K] [SEC Form 8-K filed by ImmuCell Corporation](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-immucell-corporation-6743901)
- 2026-10-12 20:05 UTC [Earnings Date] [ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results](https://www.quantisnow.com/insight/immucell-announces-a-46-increase-in-product-sales-in-quarter-6743722)
- 2026-08-13 20:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ImmuCell Corporation](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-immucell-corporation-6680445)
- 2026-08-13 20:07 UTC [SEC Form 8-K] [ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/immucell-corporation-filed-sec-form-8-k-results-of-operations-and-6680384)
- 2026-08-13 20:05 UTC [Earnings Date] [ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026](https://www.quantisnow.com/insight/immucell-announces-unaudited-financial-results-for-the-quarter-ended-june-6680217)
- 2026-08-06 20:05 UTC [Earnings Date] [ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026](https://www.quantisnow.com/insight/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-6668779)
- 2026-07-09 20:08 UTC [SEC Form 8-K] [ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/immucell-corporation-filed-sec-form-8-k-results-of-operations-and-6633019)
- 2026-07-09 20:05 UTC [Earnings Date] [ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results](https://www.quantisnow.com/insight/immucell-announces-a-12-increase-in-product-sales-in-q2-6632946)
- 2026-06-22 12:33 UTC [Insider Buy] [President and CEO Te Boekhorst Paul Francis Olivier bought $75,960 worth of shares (8,000 units at $9.49), increasing direct ownership by 82% to 17,785 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-te-boekhorst-paul-francis-olivier-bought-75960-6610170)
- 2026-06-17 18:19 UTC [SEC Form 8-K] [ImmuCell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/immucell-corporation-filed-sec-form-8-k-submission-of-matters-to-6606386)
- 2026-06-10 20:05 UTC [SEC Form 8-K] [ImmuCell Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/immucell-corporation-filed-sec-form-8-k-regulation-fd-disclosure-financial-6597032)
- 2026-05-14 20:09 UTC [SEC Form 8-K] [ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/immucell-corporation-filed-sec-form-8-k-results-of-operations-and-6553889)
- 2026-05-14 20:07 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ImmuCell Corporation](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-immucell-corporation-6553855)
- 2026-05-14 20:05 UTC [Earnings Date] [ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026](https://www.quantisnow.com/insight/immucell-announces-unaudited-financial-results-for-the-quarter-ended-march-6553649)
- 2026-05-13 20:07 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by ImmuCell Corporation](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-immucell-corporation-6550783)
- 2026-05-08 21:00 UTC [SEC Form 8-K] [ImmuCell Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/immucell-corporation-filed-sec-form-8-k-entry-into-a-material-6542791)
- 2026-05-07 20:05 UTC [Earnings Date] [ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026](https://www.quantisnow.com/insight/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-6538769)
- 2026-04-24 12:00 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by ImmuCell Corporation](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-immucell-corporation-6513669)
- 2026-04-23 16:29 UTC [SEC Form 3] [SEC Form 3 filed by new insider Dimarco Anthony](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-dimarco-anthony-6512145)
- 2026-04-23 16:26 UTC [SEC Form 3] [SEC Form 3 filed by new insider Guillemette Gilles](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-guillemette-gilles-6512143)
- 2026-04-16 20:03 UTC [SEC Form 4] [SEC Form 4 filed by Turner Kathy V](https://www.quantisnow.com/insight/sec-form-4-filed-by-turner-kathy-v-6503075)
- 2026-04-16 20:02 UTC [SEC Form 4] [SEC Form 4 filed by Tomsche David Scott](https://www.quantisnow.com/insight/sec-form-4-filed-by-tomsche-david-scott-6503029)
- 2026-04-16 19:59 UTC [SEC Form 4] [SEC Form 4 filed by Basse Gloria F](https://www.quantisnow.com/insight/sec-form-4-filed-by-basse-gloria-f-6502990)
- 2026-04-16 19:57 UTC [SEC Form 4] [SEC Form 4 filed by Wainman Paul R](https://www.quantisnow.com/insight/sec-form-4-filed-by-wainman-paul-r-6502989)
- 2026-04-14 20:41 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by ImmuCell Corporation](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-immucell-corporation-6499801)
- 2026-04-14 19:40 UTC [SEC Form 4] [SEC Form 4 filed by Gathagan Bryan K.](https://www.quantisnow.com/insight/sec-form-4-filed-by-gathagan-bryan-k-6499386)
- 2026-04-14 19:39 UTC [SEC Form 4] [SEC Form 4 filed by Wainman Paul R](https://www.quantisnow.com/insight/sec-form-4-filed-by-wainman-paul-r-6499385)
- 2026-04-14 19:38 UTC [SEC Form 4] [SEC Form 4 filed by Tomsche David Scott](https://www.quantisnow.com/insight/sec-form-4-filed-by-tomsche-david-scott-6499384)
- 2026-04-14 19:37 UTC [SEC Form 4] [SEC Form 4 filed by Brockmann Bobbi Jo](https://www.quantisnow.com/insight/sec-form-4-filed-by-brockmann-bobbi-jo-6499383)
- 2026-04-14 19:36 UTC [SEC Form 4] [SEC Form 4 filed by Rosgen Steven T.](https://www.quantisnow.com/insight/sec-form-4-filed-by-rosgen-steven-t-6499382)
- 2026-04-14 19:34 UTC [SEC Form 4] [SEC Form 4 filed by Basse Gloria F](https://www.quantisnow.com/insight/sec-form-4-filed-by-basse-gloria-f-6499380)
- 2026-04-13 23:18 UTC [SEC Form 8-K] [ImmuCell Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/immucell-corporation-filed-sec-form-8-k-leadership-update-other-events-6498482)
- 2026-04-13 20:38 UTC [Earnings Date] [ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors](https://www.quantisnow.com/insight/immucell-bolsters-its-innovation-strategy-with-appointments-of-dr-gilles-6498073)
- 2026-04-08 20:05 UTC [SEC Form 8-K] [ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/immucell-corporation-filed-sec-form-8-k-results-of-operations-and-6492844)
- 2026-04-08 20:05 UTC [Earnings Date] [ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results](https://www.quantisnow.com/insight/immucell-announces-a-284-increase-in-product-sales-in-q1-6492801)
- 2026-04-01 13:06 UTC [SEC Form 3] [SEC Form 3 filed by new insider Turner Kathy V](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-turner-kathy-v-6481125)
- 2026-03-30 21:34 UTC [SEC Form 10-K] [SEC Form 10-K filed by ImmuCell Corporation](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-immucell-corporation-6476889)
- 2026-03-24 23:57 UTC [SEC Form 4] [SEC Form 4 filed by Brigham Michael F](https://www.quantisnow.com/insight/sec-form-4-filed-by-brigham-michael-f-6467788)
- 2026-03-23 13:47 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Te Boekhorst Paul Francis Olivier](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-te-boekhorst-paul-francis-6464652)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ICCC
- Earnings history: https://www.quantisnow.com/earnings/ICCC
- Dividend history: https://www.quantisnow.com/dividends/ICCC
- Insider transactions: https://www.quantisnow.com/insiders/ICCC
- Options chain: https://www.quantisnow.com/options/ICCC
- SEC 8-K filings only: https://www.quantisnow.com/company/ICCC/8-k
- RSS and alerts for ICCC: https://www.quantisnow.com/docs/rss-feeds.md